These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 39093638)

  • 21. The Structure and Classification of Botulinum Toxins.
    Dong M; Stenmark P
    Handb Exp Pharmacol; 2021; 263():11-33. PubMed ID: 31792680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.
    Dolly JO; Wang J; Zurawski TH; Meng J
    FEBS J; 2011 Dec; 278(23):4454-66. PubMed ID: 21645262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of Botulinum Neurotoxin Synthesis and Toxin Complex Formation by Arginine and Glucose in Clostridium botulinum ATCC 3502.
    Fredrick CM; Lin G; Johnson EA
    Appl Environ Microbiol; 2017 Jul; 83(13):. PubMed ID: 28455330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How Does Botulinum Toxin Inhibit Itch?
    Gazerani P
    Toxins (Basel); 2022 Oct; 14(10):. PubMed ID: 36287970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Future aspects of botulinum neurotoxins.
    Aoki KR
    J Neural Transm (Vienna); 2008; 115(4):567-73. PubMed ID: 17557128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three enzymatically active neurotoxins of Clostridium botulinum strain Af84: BoNT/A2, /F4, and /F5.
    Kalb SR; Baudys J; Smith TJ; Smith LA; Barr JR
    Anal Chem; 2014 Apr; 86(7):3254-62. PubMed ID: 24605815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Botulinum neurotoxins in the treatment of refractory pain.
    Jabbari B
    Nat Clin Pract Neurol; 2008 Dec; 4(12):676-85. PubMed ID: 19043424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Expanding Therapeutic Utility of Botulinum Neurotoxins.
    Fonfria E; Maignel J; Lezmi S; Martin V; Splevins A; Shubber S; Kalinichev M; Foster K; Picaut P; Krupp J
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29783676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical analysis in the advancement of cell-based assays for botulinum neurotoxin.
    Ambrin G; Cai S; Singh BR
    Crit Rev Microbiol; 2023 Feb; 49(1):1-17. PubMed ID: 35212259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic use of botulinum toxin in migraine: mechanisms of action.
    Ramachandran R; Yaksh TL
    Br J Pharmacol; 2014 Sep; 171(18):4177-92. PubMed ID: 24819339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central effects of tetanus and botulinum neurotoxins.
    Caleo M; Schiavo G
    Toxicon; 2009 Oct; 54(5):593-9. PubMed ID: 19264088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transient Receptor Potential Channels and Botulinum Neurotoxins in Chronic Pain.
    Go EJ; Ji J; Kim YH; Berta T; Park CK
    Front Mol Neurosci; 2021; 14():772719. PubMed ID: 34776867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability of Botulinum Toxins: Challenges and Opportunities for the Future.
    Rasetti-Escargueil C; Lemichez E; Popoff MR
    Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30217070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-apoptotic activity of hemagglutinin-33 and botulinum neurotoxin and its implications to therapeutic and countermeasure issues.
    Kumar R; Zhou Y; Ghosal K; Cai S; Singh BR
    Biochem Biophys Res Commun; 2012 Jan; 417(2):726-31. PubMed ID: 22182409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum Neurotoxins beyond Neurons: Interplay with Glial Cells.
    Luvisetto S
    Toxins (Basel); 2022 Oct; 14(10):. PubMed ID: 36287971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Approaches of Botulinum Toxin in Gynecology.
    Moga MA; Dimienescu OG; Bălan A; Scârneciu I; Barabaș B; Pleș L
    Toxins (Basel); 2018 Apr; 10(4):. PubMed ID: 29690530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response.
    Dolimbek BZ; Jankovic J; Atassi MZ
    Immunol Invest; 2002; 31(3-4):247-62. PubMed ID: 12472183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum toxin in cancer therapy-current perspectives and limitations.
    Grenda T; Grenda A; Krawczyk P; Kwiatek K
    Appl Microbiol Biotechnol; 2022 Jan; 106(2):485-495. PubMed ID: 34951660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering of Botulinum Neurotoxins for Biomedical Applications.
    Webb RP
    Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29882791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of botulinum neurotoxins with synaptic vesicle protein complexes.
    Baldwin MR; Barbieri JT
    Toxicon; 2009 Oct; 54(5):570-4. PubMed ID: 19362106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.